AraC review

AraC, an antineoplastic medication, slows down the growth and spread of cancer cells in the body to effectively cure certain types of cancer.


AraC is usable under the brand names DepoCyt, Tarabine PFS, and Cytosar U and is given to patients with acute myeloid leukemia and lymphomas. It can also be used to cure herpes virus infections because of its antiviral properties.

AraC is usable in various forms. It can be injected into the veins through cannula, a fine tube placed in the back of the hand. It can also be administered through a thin plastic tube inserted beneath the skin into a vein. Alternatively, it can be given through a tube placed inside the PICC line, or through infusion via the cannula.


The dosage is dependent on the condition being treated, as well as the patient's response to therapy, the stage of cancer, the size of the body, and the other medicaments being used.

Treatment is usually daily for a certain period followed by a break. The treatment schedule is usually then repeated after the break.


AraC may result in various side effects, including a decreased resistance to infection, which can be experienced a week after taking AraC. This is due to the reduction of white blood cells, making a patient more likely to develop infections.

Patients may experience bleeding since AraC decreases the production of platelets instrumental in making the blood clot. Patients should inform their doctor immediately if they experienced abnormal bleeding like epistaxiss, bleeding gums, and blood spots.

Patients taking AraC may experience a decrease in red blood cells, or anemia. This could result in the patient becoming exhausted or breathless.

Patients may also experience vomiting or nausea. This usually occurs once the patient takes AraC and may last for a couple of hours. Doctors often prescribe anti-emetic medication to reduce these side effects.

AraC may also result in patients having diarrhea and can often be remedied by the patient taking in more fluids like water.

Other side effects include loss of appetite, increased uric acid level in the blood, sore ulcers and mouth, taste changes, and gritty eyes.


Cancer often increases the chances of a patient developing thrombosis, and this risk can be further increased when undergoing chemotherapy. Blood clots often cause symptoms like pain and swelling of the leg, chest pains and breathlessness. Patients should inform their doctor if they experience any of these symptoms while taking AraC.


Some medicaments may interact negatively when taken with AraC. Patients should tell their doctor about any medication, whether prescription or non-prescription that they are taking.

Patients may also experience pain at the injection site when the medication is being administered. Patients should inform their doctor or nurse of the pain so they can help in reducing the painful feeling.


AraC may also affect the fertility of the patients who are using it. It is also not urgeed for pregnant women as it can harm the developing fetus.

Arac has the following structural formula:

Chemical structure of arac

 Molecular formula of arac is C9H13N3O5
 Chemical IUPAC Name is 4-amino-1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
 Molecular weight is 243.217 g/mol
 Arac available : 100mg tablets, 500mg tablets, 1g tablets and 2g tablets

Generic name: Cytarabine

Brand name(s): Alexan, Arabinocytidine, Arabinosylcytosine, Arabitin, Aracytidine, Aracytin, Aracytine, Arafcyt, Citarabina, Cytarabin, Cytarabina, Cytarabinoside, Cytarabinum, Cytarbel, Cytosar, Cytosine, Depocyt, Erpalfa, Iretin, Spongocytidine, Tarabine, Udicil

  Your AraC review